Capricor Therapeutics (NASDAQ:CAPR) Given Buy Rating at HC Wainwright

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report)'s stock had its "buy" rating reissued by HC Wainwright in a research note issued on Friday,Benzinga reports. They presently have a $77.00 price objective on the biotechnology company's stock.

Other equities analysts also recently issued research reports about the stock. Cantor Fitzgerald restated an "overweight" rating and set a $30.00 price objective on shares of Capricor Therapeutics in a report on Wednesday, May 14th. Roth Capital initiated coverage on shares of Capricor Therapeutics in a research report on Tuesday, May 20th. They set a "buy" rating and a $31.00 target price on the stock. Finally, Wall Street Zen cut shares of Capricor Therapeutics from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd. One analyst has rated the stock with a sell rating and six have given a buy rating to the stock. According to data from MarketBeat.com, Capricor Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $35.50.

Capricor Therapeutics Stock Performance

CAPR traded down $2.16 during trading on Friday, hitting $11.78. The stock had a trading volume of 3,082,158 shares, compared to its average volume of 1,816,820. The stock has a 50 day simple moving average of $10.72 and a two-hundred day simple moving average of $12.77. Capricor Therapeutics has a twelve month low of $3.52 and a twelve month high of $23.40. The company has a market capitalization of $538.08 million, a PE ratio of -11.11 and a beta of 0.84.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last posted its quarterly earnings data on Tuesday, May 13th. The biotechnology company reported ($0.53) earnings per share for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.20). Capricor Therapeutics had a negative return on equity of 112.95% and a negative net margin of 146.86%. The business had revenue of $2.73 million during the quarter, compared to analyst estimates of $3.16 million. During the same period in the previous year, the business earned ($0.31) EPS. On average, equities research analysts anticipate that Capricor Therapeutics will post -1.21 EPS for the current year.

Institutional Trading of Capricor Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. Summit Investment Advisors Inc. raised its holdings in shares of Capricor Therapeutics by 54.1% during the fourth quarter. Summit Investment Advisors Inc. now owns 3,832 shares of the biotechnology company's stock worth $53,000 after purchasing an additional 1,345 shares during the last quarter. Russell Investments Group Ltd. raised its stake in shares of Capricor Therapeutics by 172.8% during the 4th quarter. Russell Investments Group Ltd. now owns 4,652 shares of the biotechnology company's stock valued at $64,000 after buying an additional 2,947 shares during the last quarter. Virtus ETF Advisers LLC acquired a new position in shares of Capricor Therapeutics in the 4th quarter valued at about $68,000. AlphaQuest LLC purchased a new stake in shares of Capricor Therapeutics in the fourth quarter worth about $78,000. Finally, New York State Common Retirement Fund grew its holdings in Capricor Therapeutics by 625.0% during the fourth quarter. New York State Common Retirement Fund now owns 5,800 shares of the biotechnology company's stock worth $80,000 after acquiring an additional 5,000 shares during the period. 21.68% of the stock is currently owned by institutional investors and hedge funds.

About Capricor Therapeutics

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.